Track topics on Twitter Track topics that are important to you
WALTHAM, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the appointment of Elizabeth Keiley as General Counsel. Ms. Keiley’s primary responsibility will be to manage the Company’s legal activities and to lead its compliance and corporate governance functions.
Manos Perros, Chief Executive Officer of Entasis, commented, “Elizabeth brings invaluable experience and a strong track record to this role, as Entasis progresses into late-stage clinical development and potentially commercialization. Elizabeth’s depth of experience and her proven expertise in corporate governance, compliance, intellectual property strategy and licensing, make her uniquely qualified to help our team as we continue to develop our company.”
“This is an exciting time to be joining Entasis as the Company prepares to transition into a commercial-stage company with multiple late-stage clinical candidates,” said Ms. Keiley. “I aim to utilize my experience in navigating the legal and regulatory requirements for development and commercialization of Entasis’ innovative pathogen-specific, multi-drug resistant antimicrobial therapies.”
Ms. Keiley is a seasoned attorney and has served in several in-house counsel positions for various healthcare companies. Prior to joining Entasis, Ms. Keiley was Senior Vice President, General Counsel at Oxford Immunotec, a U.K.-based global, high-growth diagnostics company focused on developing and commercializing proprietary assays for immunology and infectious disease. Previously, Ms. Keiley served as the Assistant General Counsel of Zimmer, Inc., a subsidiary of Zimmer Holdings, Inc., the world’s largest pure-play orthopedic device manufacturer. Earlier, she was a trial lawyer and partner with Wildman, Harrold, Allen & Dixon in Chicago, Illinois where she represented clients in a wide variety of commercial disputes and transactions.
Ms. Keiley earned her bachelor’s degree in psychology and philosophy from Boston College and a J.D. from Loyola University School of Law.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ targeted-design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting A. baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.
Entasis Company Contact
Investor Relations Contact
The Ruth Group
The Ruth Group
Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...